Either shorts covering, or a pre-arranged sell of shares from past offering. After hours is the p0erfect time to do something like this because of very little on bid and ask...if anything. Hopefully this means those shares are in safer hands now than the fund who just wants to run the financing scam over and over again.
yesterday after hours volume 603k.
Can u explain 650k volume and only.3% -ve, it has traded more than 5% of public float
ALT and TPST don't seem to have acquired a partner yet either. Does this mean they too won't get one? No it doesn't!
ALT stock has doubled in 2 days, pharma co will grab small cap if they see something as promising. Look at TPST, even now it is 8x of the lows.
I think with Nicotine, hypertension and diabetes drug candidate, many top companies should be accumulating hand over fist, especially all institutions investors.
Since they r not doing it, I don't see Lexx will meet same.fate as TPST or other pharma with 30-50x from these . levels
Bumka is too busy playing golf on our dime.
Deals like this take time, large corporations move at a snails pace at times. I am confident we will get something from LEXX in time with the nicotine. We may not like the pace large corps move at but we are at their mercy when it comes to the deals. It is in their time, not ours unfortunately.
Why didn't anyone ask him about human trials of Nicotine, why none of top Tobacco companies didn't venture into it even though he has clinically proven it has better absorbing rate than on the market products
The issue with Lexxy is , all the test are not getting converted into deals and that's the history and fact. So how r u so convinced this one will ?
Interview with Chris Bunka, CEO of Lexaria convinces me you have to buy this stock now...............p 6
These results should definitely get noticed by Novo Nordisk. Hopefully a collaboration with funding is in the cards!
Hello Novo Nordisk, guess what?
Then if they find efficacy in turning Ozempic into a pill...<<<insert rocket ship emoji>>>.
"This Study is not complete and additional results will be reported, likely in two tranches: Lexaria has also collected blood glucose data and expects to release those interim results imminently. Then, once the cross-over Study visit as described below has been conducted, final results from the Study should be available in late December or early January."
Substantial reductions in Blood Glucose will be a real impetus for this stock!
"During fiscal 2023, Lexaria has been working diligently with its third-party regulatory and clinical advisors in the development of its IND study protocol, has interviewed and selected its contract research organization, InClin Inc. as announced on April 24, 2023, and has been developing its clinical trial DehydraTECH-CBD drug product in order to obtain the stability data needed for its IND application to the FDA. As announced in its news release august 30, 2023, Lexaria is waiting on one of its third-party material suppliers to complete certain analytical and stability testing, which we expect to be completed prior to the end of the calendar year, to be followed with the filing of our IND application with the FDA."
They were supposed to have a deal with Altria bunka did a fine job with that one !
None of the Tobacco companies or for that matter any other company has approached Lexxy after their human nicotine trial and that tells a lot about their studies.
Something just doesn't add up right, the IND application might not even qualify
Canadian health experts call for immediate suspension of sales of nicotine pouches. Physicians for Smoke-Free Canada Executive Director Cynthia Callard called on federal health authorities to place an immediate suspension of the sale of nicotine pouches “until measures can be put in place to protect children in the nicotine market,”
Biggest problem is delivery
1> even after good results of nicotine human trials, no deals with any big tobacco company
2> no update on high blood pressure IND application
3> how do we trust if new studies on diabetic and weight loss drugs will yield any results based on above two issues.
Bunka will continue to burn cash without any results
No blame for honest underpaid ($30k/mo plus perks/options etc. ) CEO BUNKO and his side kick $300k plus a year with more options this past week Dr John -- LOL
And most longs would barely be in the green
Amazing how even going to $20 it would still be down 73% from All time high.
Yep, we just need a catalyst.
Repeat of TPST. Went from.23 cents to $10 in 2 days with 13mil float.
I am expecting lexxy to touch $20
This was posted recently on the Lexaria Bioscience Investors Group Facebook page by a member.
"No rumours at all that I know of. There is a couple big hitters that are buying in right now. Friends of a friend of mine. Between my friend, myself and our friends there will probably be a bit more than 15% ownership in good hands.. My hope is that there won't be enough stock out there to mess around with. Naked shorts could easily get caught chasing 🤞
But when they are done buying will there be a big pullback? That's the question I want answered lol"
Too bad the rest of the long term supporters are down 80% or more :/ at least someone’s making money here …
more shares for DR death??
Form 4 - Statement of changes in beneficial ownership of securities
October 30 2023 - 12:47PM
Edgar (US Regulatory)
Share On Facebook
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
DOCHERTY JOHN MARTIN
(Last) (First) (Middle)
23 MIKELEN DRIVE
PORT PERRY A6 L9L 1V1
(City) (State) (Zip) 2. Issuer Name and Ticker or Trading Symbol
Lexaria Bioscience Corp. [ LEXX ] 5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
common shares 54,075 I Private Holding Company
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options $3(1) 04/23/2020 04/23/2025 Common Shares 13,334 13,334 D
Stock Options $3(2) 04/26/2021 04/26/2026 Common Shares 18,000 31,334 D
Stock Options $3(3) 06/08/2021 06/08/2026 Common Shares 18,334 49,668 D
Stock Options $3(4) 09/01/2021 09/01/2026 Common Shares 15,000 64,668 D
Stock Options $2.91 08/29/2022 08/29/2027 Common Shares 30,000 94,668 D
Stock Options $1.15 10/26/2023 A 30,000 10/26/2023 10/26/2028 Common Shares 30,000 $0 124,668 D
Lexaria Bioscience Corp. (CSE:LXX; OTCQX:LXRP) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.
Lexaria’s DehydraTECHTM delivery technology is protected by a robust suite of patents granted or pending worldwide and is proven effective in multiple international studies in greatly assisting rapidity and quantity of absorption of a range of lipophilic (i.e., fat-soluble), bioactive molecules. By significantly enhancing the performance and experience with oral ingestion, Lexaria’s DehydraTECH delivery technology offers a viable and often healthier alternative to other delivery methods for bioactive substances in widespread use today such as inhalational delivery through smoking.
Lexaria’s patented technology, DehydraTECH™ delivers these important benefits:
Eliminates the strong tastes/odors of lipophilic compounds, without the need for unwanted sugar or sweeteners
Effects are felt within 15-20 min vs. 60-120 min.
Initial testing indirectly evidences DehydraTECH may deliver ingested molecules through the lymphatic system instead of being subject to immediate “first pass” liver exposure, potentially mitigating unwanted side effects and reducing liver biotransformation.
Bio-absorption increases up to 3 – 10X, to equate or exceed that of other routes of administration like inhalational delivery.
Lexaria’s DehydraTECH™ is designed specifically for formulating and delivering lipophilic (i.e. fat-soluble) drug payloads. It is patented or patent-pending for use with a broad range of bioactive molecules, including but not limited to:
Lexaria Bioscience Corp. (“Lexaria”) has formed the Lexaria Nicotine Corp. as its exclusive worldwide nicotine business unit. More than 89% of all nicotine that is consumed worldwide is delivered through smoking cigarettes. Approximately 6,000,000 deaths per year around the world are attributed primarily to the delivery of nicotine through the act of smoking according to the Centers for Disease Control and Prevention. Of note: “…it is primarily the toxins and carcinogens in tobacco smoke – not the nicotine – that cause illness and death.” (U.K. National Institute for Health and Care Excellence [NICE]). As many as 69% of U.S. adult smokers want to quit smoking and 43% of US adult smokers have attempted to quit in any twelve-month period. Lexaria postulates that delivery of nicotine to satisfy current demand, utilizing our patented DehydraTECH technology in common food and consumer product formats, could shift demand away from smoking cigarettes. However, ingestion of nicotine is challenging because it is poorly tolerated by the human gastrointestinal system and then significantly metabolized by the liver, thereby diminishing its overall effectiveness through edibles. Lexaria’s DehydraTECH technology offers a means to formulate ingestible product formats of nicotine and/or its analogs with higher bioavailability performance possibilities due to the benefits of our technology.
Lexaria is developing a patent suite with supporting intellectual property in the pharmaceutical sector that will supply significant long-term strategic growth potential. Lexaria Pharmaceutical Corp. is the 100%-owned subsidiary that has obtained exclusive worldwide rights to Lexaria’s patent portfolio related to pharmaceutical applications. Currently within this business unit resides the IP for Non-Steroidal Anti-Inflammatories (NSAIDs), Vitamins, hormone treatments utilizing estrogen or testosterone, phosphodiesterase inhibitors (PDE5). Additional molecules of interest could be added to this unit over time.
According to Statista.com, the global pharma industry was worth $1,105 billion in 2016, and the US pharma industry alone spent over $71 billion in 2017 on R&D: a larger R&D expenditure than the entire gross revenues of many other business sectors.. Lexaria Pharmaceutical Corp. is implementing a strategy of reinforcing its IP-suite to sufficient degree to begin partnering within this dynamic industry.
The Lexaria Hemp Co. holds exclusive global rights to the Lexaria patent portfolio related to hemp-based applications. Lexaria’s DehydraTECH technology is designed to deliver functional ingredients within hemp in oral product formats with significantly enhanced palatability, speed of effectiveness and potency as a viable and healthier alternative to conventional inhalational (i.e. smoking or vaping) administration practices. Extensively evaluated through invivo, invitro, and human clinical studies, one of the most extensive databases in the world has been collected by Lexaria related to hemp-based ingredients empowered with our DehydraTECH technology. In 2018, the World Anti Doping Agency (WADA) for the first time ever exempted cannabidiol from hemp from its list of restricted substances on its International Standards Prohibited List of substances.
Lexaria CanPharm Corp, a Canadian corporation, owns exclusive global rights to Lexaria’s intellectual property as it is applied to psychotropic bioactive molecules that act upon human CB1 and CB2 receptors in those areas of the world where it is permissible to do so. Substances that act upon these receptors and systems in the human body that affect pain, inflammation, anxiety and depression, and have also been shown to have utility against cancer and neurodegenerative conditions. Lexaria’s ground-breaking 2018 research that proved many-fold improvements in delivering an active ingredient across the blood-brain-barrier could have disruptive potential within this business sector as well as all others where Lexaria is active.
The safety and effectiveness of Lexaria’s DehydraTECH™ technology has been studied in a series of controlled and well designed in vitro and in vivo human focus studies, examining factors such as total bioabsorption directly and indirectly through surrogate biomarkers, time to onset of effectiveness, flavor appeal and quality of effectiveness. Studies to-date have focused on cannabinoid applications where Lexaria is most advanced commercially, although research is underway for the other bioactive compounds named in Lexaria’s patent portfolio and described under Commercial Applications.
Pre-Clinical Research into Lexaria’s DehydraTECH™
An in vitro absorption study was performed to assess unidirectional CBD permeability using a human epi-intestinal tissue model with various formulations in the presence of simulated intestinal fluid. The study was designed to, as closely as possible, mimic intestinal absorption as it would occur in a live subject. Samples of Lexaria’s commercially available CBD-fortified ViPova™ black tea were administered in the model compared with concentration-matched CBD control preparations that lacked Lexaria’s patented formulation and process enhancements. The study showed as much as a 499% improvement, on average, in intestinal tissue permeability with the ViPova™ black tea formulation relative to a concentration-matched CBD control preparation without any Lexaria technology enhancements. The study also showed a 325% improvement, on average, in intestinal tissue permeability comparing the ViPova™ black tea preparation to a concentration-matched CBD control preparation that utilized Lexaria`s dehydration synthesis processing methodology but lacked its fatty acid ingredient incorporation, demonstrating the power of the Lexaria technology as a whole (see Figure 1).
Following this study, a series of independent, well designed, well controlled human focus studies were undertaken corroborating Lexaria’s in vitro performance findings. A study in healthy volunteers (n=6) suggested as much as a 5-10X increase in CBD absorption, which was assessed indirectly through